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Introduction. Chronic kidney disease (CKD) is an important health 
problem in Iran, with an increasing prevalence rate. Knowledge 
about the prevalence and risk factors of this disease in different 
health jurisdictions can help in planning to control this condition.
Materials and Methods. In this cross-sectional study, 1285 
individuals aged between 20 and 60 years old were recruited. 
Participants were selected from the general population residing in 
Gonabad, Iran, via simple random sampling in 2012. Demographic 
data were collected. Urine and blood test were performed, and the 
glomerular filtration rate was estimated based on the simplified 
Modification of Diet in Renal Disease equation.
Results. Sixty-five participants (5.1%) had CKD (5.1% men and 
5% women; P = .90). The mean age was significantly higher in 
the CKD group (P = .001). Hypertension and diabetes mellitus 
were significantly more prevalent among the participants with 
CKD than those without CKD (P < .001 for both). Proteinuria was 
significantly associated with CKD, whereas a history of urinary 
tract infection, a history of nephrolithiasis, smoking, serum uric 
acid level, lipid profile, and blood glucose level were not.
Conclusions. Chronic kidney disease has a high prevalence rate 
in this part of Iran. We suggest further studies in other parts of 
our country for the better estimation of the prevalence of CKD in 
Iran and for better planning to prevent and treat this condition.
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INTRODUCTION
Chronic Kidney Disease (CKD) is one of the 
most important diseases with increasing prevalence 
worldwide and in Iran.1-6 It is a major risk factor 
for cardiovascular diseases, and also it is a reason 
for mortality with increasing prevalence in almost 
all populations all over the world.7,8 Many patients 
with CKD reach a state that is called end-stage renal 
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disease, in which the surviving is impossible unless 
with renal replacement therapy.5,8 The definition 
and guidelines for classification of CKD were 
introduced by the National Kidney Foundation’s 
Kidney Disease Outcomes Quality Initiative in 
2002, and were subsequently adopted with minor 
modifications by the international guideline group 
Kidney Disease Improving Global Outcomes in 
2004.9-11 These CKD guidelines shifted the concept 
of kidney disease from that of an uncommon 
life-threatening condition requiring care by 
nephrologists to that of a common condition with 
a range of severity meriting attention by general 
internists, and demanding strategies for prevention, 
early detection, and management.
The guidelines had a major effect on clinical 
practice, research, and public health, but also 
generated substantial controversy. Patients with 
end-stage renal disease use a disproportionate 
share of health care resources.(11, 102) The total 
cost of the end-stage renal disease program in 
the United States was approximately US $ 39.46 
billion in 2008. Medicare costs per person per year 
were nearly US $ 66 000 overall, ranging from US 
$ 26 668 for transplant patients to US $ 77 506 for 
those receiving hemodialysis therapy.12 In Iran, the 
cost of kidney transplantation without the costs of 
rehospitalization, which sometimes is equal to or 
exceeds surgery costs itself, is near US $ 10 000.13 
Costs associated with each session of hemodialysis, 
excluding surgical setup, were estimated at US 
$ 80 (US $ 12 500 annually) in Iran. On the other 
hand, recognition of CKD in its early stages can 
improve the patients’ condition and save the cost 
of CKD care.14
Some evidence suggests that CKD is not well 
recognized. Based upon findings from the National 
Health and Nutrition Examination Survey, for 
example, awareness of kidney disease in the 
United States population is low, particularly 
among certain patient subsets.15 It was reported 
that self-awareness about the disease is about 
40.5%, 29.3%, 22%, and 44.5% in stages 1, 2, 3 and 
4, respectively. Non-Hispanic blacks, men, and 
those with hypertension were less likely to know 
that they had some degrees of kidney disease. A 
similar lack of awareness was noted in a second 
study based on the National Health and Nutrition 
Examination Survey data. In this study, women 
were much less likely to be aware about their 
decreased kidney function. This was thought to 
be due to the misinterpretation of clinicians of a 
“normal” serum creatinine concentration.16
Patients who are at risk of developing CKD 
should be screened with both urine and blood 
tests for proteinuria and creatinine, respectively, to 
estimate glomerular filtration rate (GFR). Patients 
who are at risk of glomerulonephritis should be 
screened for hematuria by urinalysis.17 Because of 
the relatively low prevalence of CKD in the United 
States, massive screening in the general population 
is not recommended.18-20 Such screening, however, 
would almost certainly detect individuals who 
have no identified risk factors but are at risk for 
progression to end-stage renal disease.21,22
In Iran, there are studies about the prevalence 
and other epidemiologic aspects of CKD, but none 
of them were conducted in the northeast of Iran.23-28 
We designed a study to determine the prevalence 
of CKD and its related risk factors in individuals 
aged 20 to 60 years old in Gonabad, northeast of 
Iran, in 2012.
MATERIALS AND METHODS
This cross-sectional study was conducted in 
Gonabad, a city located in the northeast of Iran, 
in Razavi Khorasan Province. According to the 
last population census in 2011, its population is 
80 783. Three centers in this city provide healthcare 
services to all residents.29 Each health center was 
considered as a separate stratum. By using stratified 
simple random sampling, individuals from the 
communities served by each center were selected 
proportioned to each stratum. After phone calls 
and describing the study, a total number of 1285 
individuals enrolled in this survey. Inclusion 
criterion was an age between 20 years 60 years. The 
presence of acute kidney injury was considered as 
an exclusion criterion. This study complied with 
the Declaration of Helsinki and was approved 
by the local Ethics Committee. Written Informed 
consent was obtained from all participants.
The participants referred to their assigned center. 
Demographic information including age, sex, and 
educational status were collected. Laboratory tests 
were performed, including urinalysis, blood urea 
nitrogen, serum creatinine (by the Jaffe method), 
serum uric acid, fasting blood glucose, and serum 
levels of total cholesterol, high-density lipoprotein 
cholesterol, low-density lipoprotein cholesterol, 
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and triglyceride. Height,  body weight,  and 
blood pressure were also measured. Glomerular 
filtration rate was estimated using the simplified 
Modification of Diet in Renal Disease (MDRD) 
equation, as below30:
186 × (serum creatinine [mg/dL])-1.154 × (age 
[years])-0.203 × 1.212 (if African-American) × 0.742 
(if female)
A GFR less than 60 mL/min/1.73 m2 was 
considered CKD.
The SPSS software (Statistical Package for the 
Social Sciences, version 11.5, SPSS Inc, Chicago, 
Ill, USA) was used for all statistical analyses. 
Normality of distributions was assessed with 
the Kolmogorov-Smirnov test. The t test and the 
Mann-Whitney test were applied to comparisons of 
normally distributed and skewed data, respectively. 
To examine the association between categorical 
data, the chi-square and the Fisher exact tests were 
used, where appropriate.
RESULTS
A total of 1285 individuals participated in this 
study. Among those, 760 (59%) were women and 525 
(41%) were men. The mean age of the participants 
was 41.9 ± 11.6 years, and on average, the women 
were 2 years older than the men (P = .001).
Among all of the participants, 65 (5.1%) had 
CKD. While the age ranges were comparable 
between the CKD and non-CKD groups (21 to 60 
years versus 20 to 60 years, respectively), the mean 
age was significantly higher in the CKD group 
(P = .001; Table 1).
Hypertension was significantly more frequent 
among the participants with CKD than those without 
CKD (P < .001); both systolic and diastolic blood 
pressure measurements were higher on average 
in this group. The systolic blood pressure ranged 
from 100 mm Hg to 180 mm Hg in the CKD group 
80 mm Hg to 180 mmHg in the non-CKD group. 
The diastolic blood pressure ranged from 70 mm 
Hg to 100 mm Hg versus 50 mm Hg to 100 mm 
Hg in the CKD and non-CKD groups, respectively. 
Chronic kidney disease was present in 15% of 
hypertensive patients, whereas it was present 2.7% 
of the participants with normal blood pressure.
Diabetes mellitus was also more prevalent among 
those with CKD (Table 1). Chronic kidney disease 
was present in 8.8% of diabetic patients, while it 
was present in 4.2% of the nondiabetic participants.
Eight percent of the participants with a history of 
urinary tract infection had CKD, but 4.5% of those 
without a history of urinary tract infection were 
screened positive for CKD. Among individuals 
with a history of nephrolithiasis, 3 (6.3%) had 
CKD and 45 (93.7%) did not, while among those 
without a history of nephrolithiasis, 40 (4.8%) had 
CKD and 796 (95.2%) did not (P = .50; Table 1).
Serum creatinine level ranged from 1.1 mg/
dL to 10.0 mg/dL in the CKD group. Other than 
serum creatinine and blood urea nitrogen levels, 
none of the blood tests showed a significantly 
different level in the CKD group as compared 
with the non-CKD group (Table 2). Among 1194 
persons whose dipstick tests were negative for 
proteinuria, 45 (3.8%) had CKD, whereas this was 
22% in those with proteinuria (Table 2).
Participants Groups
Characteristics CKD(n = 65)
Non-CKD
(n = 1220) P
Sex
Male 27 (42) 498 (41)
Female 38 (58) 722 (59) .90
Mean age, y 48.1 ± 9.2 46.1 ± 11.7 < .001
Diabetes mellitus 9 (14) 93 (7) .04
Hypertension 22 (34) 125 (10) < .001
Mean systolic blood pressure, mm Hg 131.8 ± 20 118.7 ± 14.3 < .001
Mean diastolic blood pressure, mm Hg 82.12 ± 7.5 74.4 ± 9.7 < .001
History of urinary tract infection 7 (10) 81 (6) .18
History of nephrolithiasis 3 (4) 45 (3) .50
Smoking 4 (6) 38 (3) .13
Table 1. Demographic and Clinical Characteristics of Participants*
*values are mean ± standard deviation for age and blood pressure and frequency (percentage) for all other variables.
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DISCUSSION
Prevalence of CKD has been reported to vary 
in between studies. In our study, as mentioned 
above, the prevalence of CKD was 5.1%. In 
different studies in Iran, this prevalence was 
between 4.6% and 37.9%. Najafi and colleagues in 
Golestan Province and Barahimi and colleagues in 
Isfahan Province detected the prevalence of 4.6% 
and 4.7%, respectively.23,28 On the other hand, 
Ghaffari and coworkers reported a prevalence of 
37.9% in Urmia in West Azerbaijan in Iran.24 The 
prevalence of CKD in Fars province was reported 
to be 11.6% in year.31. One of the probable causes 
of differences in these results is the difference in 
the method of measuring the serum creatinine 
level. For example in our study, the Jaffe method 
was used for measuring it.
The other probable cause might be due to 
difference in the way of determining GFR. In some 
studies, inulin clearance or diethylene triamine 
pentaacetic acid clearance are the measuring 
methods for GFR estimation, while in some studies 
measuring of serum creatinine alone is used. The 
Cockroft-Gault equation is used for estimating 
GFR in some studies and the MDRD methods are 
applied in other ones.24-29 As mentioned above, in 
the current study, we used the MDRD method for 
calculating GFR. In Ghaffari and colleagues’ study, 
elevated serum creatinine was the only criteria for 
determining CKD and GFR was not estimated at all; 
therefore, comparison of their reported prevalence 
of 37.9% in that part of Iran with the other figures 
is not possible.24 Reports from Golestan and Isfahan 
provinces used the MDRD method and their results 
were relatively similar.23,28
Variations in the populations’ characteristics 
would be the other reason for differences between 
our result and what Ghaffari and colleagues 
reported. They studied the high-risk groups (such 
as diabetic and hypertensive patients), while our 
sample came from the general population. The 
prevalence of CKD in a study by Mahdavi-Mazdeh 
and colleagues26 was 6.5%, whereas both studies 
used the MDRD method. It would be because of 
the differences in populations too; The latter was 
on male taxi drivers in Tehran.24,26 In our study, 
there were no significant differences between men 
and women, while in most of the abovementioned 
studies, the prevalence of CKD was higher in 
women.23,26,28
CONCLUSIONS
Overall, it seems that CKD is a common health 
problem in Iran, but further studies in other parts 
of this country is recommended for the better 
estimation of CKD prevalence. This study shows 
the importance of screening for CKD. Greater 
attention to risk factors and underlying diseases 
should be placed high on the agenda.
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